ReviewClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2021
The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses.
Review in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review.Infectious diseases of poverty · 2022Pooled it
- Peptide MegaPools Approach to Evaluate the Dengue-Specific CD4 and CD8 T-Cell Response.Pathogens (Basel, Switzerland) · 2025Article
- Performance of whole blood interferon-γ release assays in SARS-CoV-2 and tuberculosis is age dependent.Infection · 2025Article
- Improving the diagnostic performance for prior COVID-19 with T-SPOT, an interferon-gamma release assay.Frontiers in microbiology · 2025Article
- Article
- Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Patients.Vaccines · 2024Article
- Cell immunity to SARS-CoV-2 after natural infection and/or different vaccination regimens.Frontiers in cellular and infection microbiology · 2024Article
- B-cell-depleted patients with persistent SARS-CoV-2 infection: combination therapy or monotherapy? A real-world experience.Frontiers in medicine · 2024Article
- Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report.Frontiers in oncology · 2024Article
- Article
- Article
- Article
- Cellular immunity reflects the persistent symptoms among COVID-19 recovered patients in Japan.Scientific reports · 2023Article
- Prevalence and functional profile of SARS-CoV-2 T cells in asymptomatic Kenyan adults.The Journal of clinical investigation · 2023Article
- The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic.Pathogens (Basel, Switzerland) · 2023Review
- Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose.International journal of molecular sciences · 2023Article
- Assessing T-Cell Immunity in Kidney Transplant Recipients with Absent Antibody Production after a 3rd Dose of the mRNA-1273 Vaccine.International journal of molecular sciences · 2022Article
- Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain.Scientific reports · 2022Article
- Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- Correlates of protection against SARS-CoV-2 infection and COVID-19 disease.Immunological reviews · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBoth humoral and cell-mediated responses are associated with immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although our understanding of the potential role of T-cell responses in the context of coronavirus disease 2019 (COVID-19) is rapidly increasing, more information is still needed.
objectivesTo provide an overview of the role of T-cell immunity in COVID-19, in the context of natural infection and post-vaccination, and discuss the potential utility of measuring SARS-CoV-2-specific T-cell responses, drawing on experience of the use of interferon-γ release assays (IGRAs) in tuberculosis (TB). SOURCES: PubMed articles up to 16 April 2021. CONTENT: T-cell responses can be detected very early in the course of COVID-19, earlier than the detection of antibody responses, and are correlated with COVID-19 outcome. Lower CD4 IMPLICATIONS: Simple assays for measuring the quantity and function of T-cell responses may have utility in the prognostication of COVID-19, and for monitoring immune responses to SARS-CoV-2 vaccination and population-based immunity to SARS-CoV-2 variants of interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.